Olemedia/E+ via Getty Images Obesity drug developer BioAge Labs ( BIOA ) has filed regulatory filings as part of its U.S. IPO.
It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the midpoint..
Olemedia/E+ via Getty Images Obesity drug developer BioAge Labs ( BIOA ) has filed regulatory filings as part of its U.S. IPO.
It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the midpoint..